These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 33474828

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):909-15. PubMed ID: 20405511
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
    Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA.
    Clin Cancer Res; 2020 May 15; 26(10):2297-2307. PubMed ID: 31969338
    [Abstract] [Full Text] [Related]

  • 49. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.
    Lancet Oncol; 2014 Aug 15; 15(9):1019-26. PubMed ID: 25042202
    [Abstract] [Full Text] [Related]

  • 50. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.
    Deyell RJ, Wu B, Rassekh SR, Tu D, Samson Y, Fleming A, Bouffet E, Sun X, Powers J, Seymour L, Baruchel S, Morgenstern DA.
    Pediatr Blood Cancer; 2019 Mar 15; 66(3):e27540. PubMed ID: 30393943
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS.
    Cancer; 2012 Feb 15; 118(4):1130-7. PubMed ID: 21761400
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 56. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Hartmann C, Weinel P, Schmid H, Grigull L, Sander A, Linderkamp C, Welte K, Reinhardt D.
    J Pediatr Hematol Oncol; 2011 Jul 15; 33(5):344-9. PubMed ID: 21572345
    [Abstract] [Full Text] [Related]

  • 57. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.
    Bisogno G, Ferrari A, Tagarelli A, Sorbara S, Chiaravalli S, Poli E, Scarzello G, De Corti F, Casanova M, Affinita MC.
    Pediatr Blood Cancer; 2021 Jul 15; 68(7):e28951. PubMed ID: 33694265
    [Abstract] [Full Text] [Related]

  • 58. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
    Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD.
    Pediatr Blood Cancer; 2017 Jan 15; 64(1):25-31. PubMed ID: 27555472
    [Abstract] [Full Text] [Related]

  • 59. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J.
    Pediatr Blood Cancer; 2013 Sep 15; 60(9):1447-51. PubMed ID: 23630159
    [Abstract] [Full Text] [Related]

  • 60. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
    Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R.
    Cancer; 2009 Jan 01; 115(1):207-16. PubMed ID: 19090012
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.